MRD assessment is assuming an increasingly important role in the management of AML. Early data suggest that FLT3-ITD MRD analysis may be a stronger predictor of outcome than many other established prognostic factors defined at diagnosis and during therapy. While at present it remains to be clarified how FLT3-ITD MRD assessment will ultimately fit into an overall AML MRD testing strategy, data available at this time suggest that FLT3-ITD MRD analysis may be quite useful clinically; laboratories should plan to offer this analysis. Here, FLT3 is linked to acute myeloid leukemia.